-
公开(公告)号：US20120015928A1
公开(公告)日：2012-01-19
申请号：US13243565
申请日：2011-09-23
申请人： Wenqing Yao , Jincong Zhuo , Meizhong Xu , Brian W. Metcalf , Chunhong He , Ding-Quan Qian , Colin Zhang
发明人： Wenqing Yao , Jincong Zhuo , Meizhong Xu , Brian W. Metcalf , Chunhong He , Ding-Quan Qian , Colin Zhang
IPC分类号： A61K31/40 , C07D221/20 , A61K31/438 , C07D471/10 , C07D241/04 , A61K31/495 , C07D401/06 , A61K31/496 , C07D413/14 , A61K31/5377 , C07D295/112 , A61K31/55 , A61K31/4439 , A61P3/04 , A61P3/10 , A61P3/08 , A61P5/48 , A61P9/12 , A61P3/06 , A61P25/28 , A61P27/06 , A61P9/00 , A61P19/10 , A61P29/00 , A61P13/12 , A61P9/04 , A61P7/02 , A61P7/00 , A61P3/00 , A61P9/10 , C12N9/99 , C07D207/12
CPC分类号： C07D207/06 , A61K31/407 , A61K31/4439 , C07D207/08 , C07D207/10 , C07D207/12 , C07D207/14 , C07D207/16 , C07D207/27 , C07D209/08 , C07D209/42 , C07D209/44 , C07D209/52 , C07D209/62 , C07D209/70 , C07D211/16 , C07D211/18 , C07D211/22 , C07D211/34 , C07D211/46 , C07D211/48 , C07D211/52 , C07D211/58 , C07D211/64 , C07D211/66 , C07D211/70 , C07D213/38 , C07D217/06 , C07D217/26 , C07D221/20 , C07D295/185 , C07D333/34 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/10 , C07D491/107 , C07D491/20 , C07D493/10 , C07D495/04 , C07D498/20 , C07D513/10
摘要： The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
摘要翻译： 本发明涉及11-和bgr的抑制剂。 1型羟基类固醇脱氢酶，盐皮质激素受体（MR）的拮抗剂及其药物组合物。 本发明的化合物可用于治疗与11-bgr的表达或活性相关的各种疾病; 羟基类固醇脱氢酶1型和/或与醛固酮过量相关的疾病。
-
公开(公告)号：US07776874B2
公开(公告)日：2010-08-17
申请号：US12136529
申请日：2008-06-10
申请人： Wenqing Yao , Jincong Zhuo , Meizhong Xu , Brian W. Metcalf , Chunhong He , Ding-Quan Qian , Colin Zhang
发明人： Wenqing Yao , Jincong Zhuo , Meizhong Xu , Brian W. Metcalf , Chunhong He , Ding-Quan Qian , Colin Zhang
IPC分类号： A61K31/443 , A61K31/4025 , A61K31/34 , C07D213/46 , C07D209/54 , C07D407/10
CPC分类号： C07D207/06 , A61K31/407 , A61K31/4439 , C07D207/08 , C07D207/10 , C07D207/12 , C07D207/14 , C07D207/16 , C07D207/27 , C07D209/08 , C07D209/42 , C07D209/44 , C07D209/52 , C07D209/62 , C07D209/70 , C07D211/16 , C07D211/18 , C07D211/22 , C07D211/34 , C07D211/46 , C07D211/48 , C07D211/52 , C07D211/58 , C07D211/64 , C07D211/66 , C07D211/70 , C07D213/38 , C07D217/06 , C07D217/26 , C07D221/20 , C07D295/185 , C07D333/34 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/10 , C07D491/107 , C07D491/20 , C07D493/10 , C07D495/04 , C07D498/20 , C07D513/10
摘要： The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
摘要翻译： 本发明涉及11-和bgr的抑制剂。 1型羟基类固醇脱氢酶，盐皮质激素受体（MR）的拮抗剂及其药物组合物。 本发明的化合物可用于治疗与11-bgr的表达或活性相关的各种疾病; 羟基类固醇脱氢酶1型和/或与醛固酮过量相关的疾病。
-
23.发明授权Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 有权取代的咪唑并哒嗪和苯并咪唑作为FGFR3的抑制剂公开(公告)号：US08754114B2
公开(公告)日：2014-06-17
申请号：US13333021
申请日：2011-12-21
申请人： Wenqing Yao , Colin Zhang , Meizhong Xu , Jincong Zhuo , Chunhong He
发明人： Wenqing Yao , Colin Zhang , Meizhong Xu , Jincong Zhuo , Chunhong He
IPC分类号： A01N43/42 , A61K31/415 , C07D235/00
CPC分类号： A61K31/5025 , A61K31/5377 , C07D235/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/12 , C07D487/04
摘要： The present invention relates to substituted imidazopyridazines and substituted benzimidazoles, as well as pharmaceutical compositions comprising the same, which are FGFR3 inhibitors useful in the treatment of cancer and other diseases.
摘要翻译： 本发明涉及取代的咪唑并哒嗪和取代的苯并咪唑，以及含有它们的药物组合物，它们是可用于治疗癌症和其它疾病的FGFR3抑制剂。
-
公开(公告)号：US08058288B2
公开(公告)日：2011-11-15
申请号：US12817887
申请日：2010-06-17
申请人： Wenqing Yao , Jincong Zhuo , Meizhong Xu , Colin Zhang , Brian W. Metcalf , Chunhong He , Ding-Quan Qian
发明人： Wenqing Yao , Jincong Zhuo , Meizhong Xu , Colin Zhang , Brian W. Metcalf , Chunhong He , Ding-Quan Qian
IPC分类号： A61K31/44 , A61K31/40 , A61K31/34 , C07D491/20
CPC分类号： C07D207/06 , A61K31/407 , A61K31/4439 , C07D207/08 , C07D207/10 , C07D207/12 , C07D207/14 , C07D207/16 , C07D207/27 , C07D209/08 , C07D209/42 , C07D209/44 , C07D209/52 , C07D209/62 , C07D209/70 , C07D211/16 , C07D211/18 , C07D211/22 , C07D211/34 , C07D211/46 , C07D211/48 , C07D211/52 , C07D211/58 , C07D211/64 , C07D211/66 , C07D211/70 , C07D213/38 , C07D217/06 , C07D217/26 , C07D221/20 , C07D295/185 , C07D333/34 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/10 , C07D491/107 , C07D491/20 , C07D493/10 , C07D495/04 , C07D498/20 , C07D513/10
摘要： The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
摘要翻译： 本发明涉及11-和bgr的抑制剂; 1型羟基类固醇脱氢酶，盐皮质激素受体（MR）的拮抗剂及其药物组合物。 本发明的化合物可用于治疗与11-bgr的表达或活性相关的各种疾病; 羟基类固醇脱氢酶1型和/或与醛固酮过量相关的疾病。
-
公开(公告)号：US07915408B2
公开(公告)日：2011-03-29
申请号：US12695636
申请日：2010-01-28
申请人： Jincong Zhuo , Colin Zhang , Meizhong Xu , Ding-Quan Qian , Wenqing Yao , Ravi Kumar Jalluri
发明人： Jincong Zhuo , Colin Zhang , Meizhong Xu , Ding-Quan Qian , Wenqing Yao , Ravi Kumar Jalluri
IPC分类号： A61K31/53 , A61K31/5377 , A61P35/00 , C07D487/04 , C07D403/04 , C07D403/14
CPC分类号： C07D487/04
摘要： The present invention is directed to [1,2,4]triazolo[4,3-b][1,2,4]triazines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
摘要翻译： 本发明涉及[1,2,4]三唑并[4,3-b] [1,2,4]三嗪及其药物组合物，其为激酶抑制剂，例如c-Met，可用于 治疗与激素途径失调相关的癌症和其他疾病。
-
公开(公告)号：US20100130467A1
公开(公告)日：2010-05-27
申请号：US12695636
申请日：2010-01-28
申请人： Jincong Zhuo , Colin Zhang , Meizhong Xu , Ding-Quan Qian , Wenqing Yao , Ravi Kumar Jalluri
发明人： Jincong Zhuo , Colin Zhang , Meizhong Xu , Ding-Quan Qian , Wenqing Yao , Ravi Kumar Jalluri
IPC分类号： A61K31/53 , C07D487/04 , A61K31/5377 , A61P35/00 , A61P35/04 , A61P9/10 , A61P11/00 , A61P13/12 , A61P1/16 , A61P37/08 , A61P29/00 , A61P37/00 , A61P9/00 , C12N5/00
CPC分类号： C07D487/04
摘要： The present invention is directed to [1,2,4]triazolo[4,3-b][1,2,4]triazines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
摘要翻译： 本发明涉及[1,2,4]三唑并[4,3-b] [1,2,4]三嗪及其药物组合物，其为激酶抑制剂，例如c-Met，可用于 治疗与激素途径失调相关的癌症和其他疾病。
-
公开(公告)号：US20080255154A1
公开(公告)日：2008-10-16
申请号：US12136529
申请日：2008-06-10
申请人： Wenqing Yao , Jincong Zhuo , Meizhong Xu , Brian W. Metcalf , Chunhong He , Ding-Quan Qian , Colin Zhang
发明人： Wenqing Yao , Jincong Zhuo , Meizhong Xu , Brian W. Metcalf , Chunhong He , Ding-Quan Qian , Colin Zhang
IPC分类号： A61K31/497 , C07D207/04 , A61K31/40 , A61K31/438 , A61P3/10 , A61P3/04 , C12N9/04 , C07D487/00 , C07D401/02
CPC分类号： C07D207/06 , A61K31/407 , A61K31/4439 , C07D207/08 , C07D207/10 , C07D207/12 , C07D207/14 , C07D207/16 , C07D207/27 , C07D209/08 , C07D209/42 , C07D209/44 , C07D209/52 , C07D209/62 , C07D209/70 , C07D211/16 , C07D211/18 , C07D211/22 , C07D211/34 , C07D211/46 , C07D211/48 , C07D211/52 , C07D211/58 , C07D211/64 , C07D211/66 , C07D211/70 , C07D213/38 , C07D217/06 , C07D217/26 , C07D221/20 , C07D295/185 , C07D333/34 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/10 , C07D491/107 , C07D491/20 , C07D493/10 , C07D495/04 , C07D498/20 , C07D513/10
摘要： The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
摘要翻译： 本发明涉及1型11-β羟基类固醇脱氢酶抑制剂，盐皮质激素受体（MR）的拮抗剂及其药物组合物。 本发明的化合物可用于治疗与1-β羟基类固醇脱氢酶1型和/或与醛固酮过量相关的疾病的表达或活性相关的各种疾病。
-
公开(公告)号：US09126927B2
公开(公告)日：2015-09-08
申请号：US13243565
申请日：2011-09-23
申请人： Wenqing Yao , Jincong Zhuo , Meizhong Xu , Brian W. Metcalf , Chunhong He , Ding-Quan Qian , Colin Zhang
发明人： Wenqing Yao , Jincong Zhuo , Meizhong Xu , Brian W. Metcalf , Chunhong He , Ding-Quan Qian , Colin Zhang
IPC分类号： C07D209/96 , C07D307/94 , C07D207/06 , C07D207/08 , C07D207/10 , C07D207/12 , C07D207/14 , C07D207/16 , C07D207/27 , C07D209/08 , C07D209/42 , C07D209/44 , C07D209/52 , C07D209/62 , C07D209/70 , C07D211/16 , C07D211/18 , C07D211/22 , C07D211/34 , C07D211/46 , C07D211/48 , C07D211/52 , C07D211/58 , C07D211/64 , C07D211/66 , C07D211/70 , C07D213/38 , C07D217/06 , C07D217/26 , C07D221/20 , C07D295/185 , C07D333/34 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/10 , C07D491/20 , C07D493/10 , C07D495/04 , C07D498/20 , C07D513/10
CPC分类号： C07D207/06 , A61K31/407 , A61K31/4439 , C07D207/08 , C07D207/10 , C07D207/12 , C07D207/14 , C07D207/16 , C07D207/27 , C07D209/08 , C07D209/42 , C07D209/44 , C07D209/52 , C07D209/62 , C07D209/70 , C07D211/16 , C07D211/18 , C07D211/22 , C07D211/34 , C07D211/46 , C07D211/48 , C07D211/52 , C07D211/58 , C07D211/64 , C07D211/66 , C07D211/70 , C07D213/38 , C07D217/06 , C07D217/26 , C07D221/20 , C07D295/185 , C07D333/34 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/10 , C07D491/107 , C07D491/20 , C07D493/10 , C07D495/04 , C07D498/20 , C07D513/10
摘要： The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
摘要翻译： 本发明涉及11-和bgr的抑制剂。 1型羟基类固醇脱氢酶，盐皮质激素受体（MR）的拮抗剂及其药物组合物。 本发明的化合物可用于治疗与11-bgr的表达或活性相关的各种疾病; 羟基类固醇脱氢酶1型和/或与醛固酮过量相关的疾病。
-
公开(公告)号：US08143251B2
公开(公告)日：2012-03-27
申请号：US13033918
申请日：2011-02-24
申请人： Jincong Zhuo , Colin Zhang , Meizhong Xu , Ding-Quan Qian , Wenqing Yao , Ravi Kumar Jalluri
发明人： Jincong Zhuo , Colin Zhang , Meizhong Xu , Ding-Quan Qian , Wenqing Yao , Ravi Kumar Jalluri
IPC分类号： A61K31/53 , A61P35/00 , C07D487/04 , C07D403/04 , C07D403/14
CPC分类号： C07D487/04
摘要： The present invention is directed to [1,2,4]triazolo[4,3-b][1,2,4]triazines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
摘要翻译： 本发明涉及[1,2,4]三唑并[4,3-b] [1,2,4]三嗪及其药物组合物，其为激酶抑制剂，例如c-Met，可用于 治疗与激素途径失调相关的癌症和其他疾病。
-
公开(公告)号：US07683060B2
公开(公告)日：2010-03-23
申请号：US11834226
申请日：2007-08-06
申请人： Jincong Zhuo , Colin Zhang , Meizhong Xu , Ding-Quan Qian , Wenqing Yao , Ravi Kumar Jalluri
发明人： Jincong Zhuo , Colin Zhang , Meizhong Xu , Ding-Quan Qian , Wenqing Yao , Ravi Kumar Jalluri
IPC分类号： C07D487/04 , C07D403/04 , C07D403/14 , A61K31/53 , A61K31/5377 , A61P35/00
CPC分类号： C07D487/04
摘要： The present invention is directed to [1,2,4]triazolo[4,3-b][1,2,4]triazines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
摘要翻译： 本发明涉及[1,2,4]三唑并[4,3-b] [1,2,4]三嗪及其药物组合物，其为激酶抑制剂，例如c-Met，可用于 治疗与激素途径失调相关的癌症和其他疾病。
-
-
-
-
-
-
-
-
-
搜索结果
43 条记录 (耗时 0.043 秒)
